Braveheart Bio Stock (NASDAQ:BRVE)
Previous Close
$27.76
52W Range
$24.61 - $32.00
50D Avg
$27.52
200D Avg
$27.52
Market Cap
$2.04B
Avg Vol (3M)
$557.80K
Beta
-
Div Yield
-
BRVE Company Profile
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.